S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Merck to End Clinical Development of Lung Cancer Drug Tecemotide (2014/9/12)|
|Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment (2014/7/10)|
|Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results|
|Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer|
|Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma|
|Jazz Pharmaceuticals Announces Second Quarter 2014 Financial Results And Updated Guidance|
|Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference|
|BioMarin to Attend Upcoming Investor Conferences in London|
|BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET|
|BioMarin Announces Health Canada Approval of VIMIZIM™ (elosulfase alfa) for the Treatment of Morquio A Syndrome|
Click above to view more mutual fund data and stats for mkgay - Merck KGaA ADR.